Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GSKGLAXF 73 3-Year FCF Growth Rate is -2.90% as of Jun. 2026. GuruFocus rates GLAXF with a GF Score™ of 73/100 and a GF Value™ of $21.90 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 657 Drug Manufacturers companies, GSK ranks worse than 62.71% on this metric.
During the past 12 months, GSK's average Free Cash Flow per Share Growth Rate was 15.80% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -2.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -8.40% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 7.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of GSK was 266.60% per year. The lowest was -37.90% per year. And the median was 4.65% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
GSK 3-Year FCF Growth Rate Related Terms
GLAXF vs LLY, JNJ, ABBV: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - General subindustry, GSK's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where GSK's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of -2.90% mean?
GSK (GLAXF) has a 3-Year FCF Growth Rate of -2.90% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for GSK and its competitors. According to the industry distribution chart, GSK ranks #412 out of 657 companies in the Drug Manufacturers industry, placing it in the top 62.7%.
Is GSK's 3-Year FCF Growth Rate too high?
GSK's current 3-Year FCF Growth Rate is -2.90%. Based on the distribution chart, GSK ranks #412 out of 657 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GSK has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's 3-Year FCF Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #412 out of 657 companies for 3-Year FCF Growth Rate. This places GSK in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 8.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 8.80, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for GSK and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current 3-Year FCF Growth Rate is -2.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.90, compared to a current price of $25.57 — trading 16.7% above its estimated fair value. The current 3-Year FCF Growth Rate is -2.90%. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For GSK (GLAXF), the current 3-Year FCF Growth Rate is -2.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.57 is trading 16.7% above its estimated GF Value™ of $21.90.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
3-Year FCF Growth Rate: -2.90%
GF Value™: $21.90 vs. price of $25.57 (16.7% above fair value)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score
Get the complete analysis for GLAXF
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
